![Lynparza ( Olaparib ) 150Mg Tablets for Personal, Packaging: Strip, Rs 35500 /strip | ID: 21504406255 Lynparza ( Olaparib ) 150Mg Tablets for Personal, Packaging: Strip, Rs 35500 /strip | ID: 21504406255](https://5.imimg.com/data5/ZA/DM/XA/ANDROID-1730486/img-20190930-133001-jpg-500x500.jpg)
Lynparza ( Olaparib ) 150Mg Tablets for Personal, Packaging: Strip, Rs 35500 /strip | ID: 21504406255
![Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5719faac-ad36-4b3d-b41c-9515f062d51d/gr2_lrg.jpg)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
![Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1a4f424f-5880-4aa9-a406-97ba20064e08/gr2_lrg.jpg)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
![A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes - European Journal of Cancer A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/91c865f0-64f2-4588-992c-686afc8e89fc/gr1_lrg.jpg)
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes - European Journal of Cancer
![Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e80a7fd3-fef3-4f03-a034-5d7f381032b2/gr1_lrg.gif)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
![Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a99e144d-cde9-44fe-8205-4aa16e8afec3/gr3_lrg.jpg)